Archive for October 2025
2 New Published Studies Highlight SeptiCyte RAPID’s Strong Performance and Clinical Utility in Post Cardiac Surgery Patients
SeptiCyte® RAPID scales with other measures of infection and clinical severity and outperforms traditional biomarkers in discriminating infection status SEATTLE and BRISBANE, Australia, Oct. 23, 2025 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced publication of two studies in the International Journal of Molecular Sciences and Journal of Critical…
Read MoreInternational Journal of Molecular Sciences: Early Use of Innovative Biomarkers Such as Mid-Regional Pro-Adrenomedullin and SeptiCyte® RAPID in Post-Cardiac Surgery Patients
Abstract: Prognostic uncertainty and missed diagnoses of sepsis remain frequent after cardiopulmonary bypass (CPB) surgery, where systemic inflammatory response (SIRS) arises from surgical trauma, blood activation in the extracorporeal circuit, ischemia/reperfusion injury, and endotoxin release. Among innovative biomarkers, pro-adrenomedullin (pro-ADM), particularly its stable fragment mid-regional pro-adrenomedullin (MR-proADM), has shown promise for detecting endothelial dysfunction and…
Read More